CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Hikma Pharmaceuticals PLC - HIK CFD

18.00
0.06%
Market Trading Hours* (UTC) Opens on Tuesday at 07:00

Mon - Fri: 07:00 - 11:00 11:03 - 15:30

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.33
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.025289 %
Charges from full value of position ($-4.80)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.025289%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003372 %
Charges from full value of position ($0.64)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003372%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency GBP
Margin 5%
Stock exchange United Kingdom of Great Britain and Northern Ireland
Commission on trade 0%

*Information provided by Capital.com

Hikma Pharmaceuticals PLC ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 17.99
Open* 17.93
1-Year Change* 0.5%
Day's Range* 17.9 - 18.09
52 wk Range 16.08-22.22
Average Volume (10 days) 707.17K
Average Volume (3 months) 11.60M
Market Cap 4.25B
P/E Ratio 37.11
Shares Outstanding 221.08M
Revenue 2.15B
EPS 0.52
Dividend (Yield %) 2.56525
Beta 0.43
Next Earnings Date Feb 22, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Apr 15, 2024 18.00 0.17 0.95% 17.83 18.11 17.82
Apr 12, 2024 17.99 -0.24 -1.32% 18.23 18.32 17.76
Apr 11, 2024 18.07 0.33 1.86% 17.74 18.15 17.66
Apr 10, 2024 17.85 -0.21 -1.16% 18.06 18.20 17.78
Apr 9, 2024 18.07 -0.13 -0.71% 18.20 18.30 18.07
Apr 8, 2024 18.45 0.10 0.54% 18.35 18.49 18.28
Apr 5, 2024 18.58 0.13 0.70% 18.45 18.60 18.29
Apr 4, 2024 18.68 0.32 1.74% 18.36 18.77 18.36
Apr 3, 2024 18.59 0.02 0.11% 18.57 18.68 18.34
Apr 2, 2024 18.79 -0.09 -0.48% 18.88 18.93 18.62
Mar 28, 2024 19.22 0.40 2.13% 18.82 19.34 18.80
Mar 27, 2024 18.72 0.14 0.75% 18.58 18.74 18.48
Mar 26, 2024 18.70 -0.13 -0.69% 18.83 18.93 18.47
Mar 25, 2024 18.64 -0.49 -2.56% 19.13 19.13 18.64
Mar 22, 2024 19.14 0.33 1.75% 18.81 19.16 18.76
Mar 21, 2024 18.69 -0.56 -2.91% 19.25 19.25 18.16
Mar 20, 2024 19.37 0.20 1.04% 19.17 19.59 19.06
Mar 19, 2024 19.02 0.19 1.01% 18.83 19.03 18.73
Mar 18, 2024 18.77 0.45 2.46% 18.32 18.83 18.32
Mar 15, 2024 18.48 -0.04 -0.22% 18.52 18.63 18.37

Hikma Pharmaceuticals PLC Events

Time (UTC) Country Event
Thursday, April 25, 2024

Time (UTC)

06:00

Country

GB

Event

April 2024 Hikma Pharmaceuticals PLC Trading Statement Release
April 2024 Hikma Pharmaceuticals PLC Trading Statement Release

Forecast

-

Previous

-

Time (UTC)

10:00

Country

GB

Event

Hikma Pharmaceuticals PLC Annual Shareholders Meeting
Hikma Pharmaceuticals PLC Annual Shareholders Meeting

Forecast

-

Previous

-
Friday, April 26, 2024

Time (UTC)

10:00

Country

GB

Event

Hikma Pharmaceuticals PLC Annual Shareholders Meeting
Hikma Pharmaceuticals PLC Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 2517 2553 2341 2203 2076
Revenue 2517 2553 2341 2203 2076
Cost of Revenue, Total 1252 1252 1128 1108 1004
Gross Profit 1265 1301 1213 1095 1072
Total Operating Expense 2208 1955 1739 1669 1731
Selling/General/Admin. Expenses, Total 509 488 464 453 437
Research & Development 144 143 137 126 118
Unusual Expense (Income) 200 -39 -76 -60 104
Other Operating Expenses, Total 11 38 44 8 68
Operating Income 309 598 602 534 345
Interest Income (Expense), Net Non-Operating -65 -41 -33 -27 -39
Other, Net -11 -13 -11 -16 -13
Net Income Before Taxes 233 544 558 491 293
Net Income After Taxes 191 420 430 487 285
Minority Interest -3 1 1 -1 -3
Net Income Before Extra. Items 188 421 431 486 282
Net Income 188 421 431 486 282
Income Available to Common Excl. Extra. Items 188 421 431 486 282
Income Available to Common Incl. Extra. Items 188 421 431 486 282
Dilution Adjustment 0
Diluted Net Income 188 421 431 486 282
Diluted Weighted Average Shares 225 233 238 243 242
Diluted EPS Excluding Extraordinary Items 0.83556 1.80687 1.81092 2 1.16529
Dividends per Share - Common Stock Primary Issue 0.55789 0.55055 0.50649 0.4714 0.37647
Diluted Normalized EPS 2.03111 1.66094 1.4958 2.16049 1.90496
Total Extraordinary Items 0
Depreciation / Amortization 92 73 42 34
Jun 2023 Dec 2022 Jun 2022 Dec 2021 Jun 2021
Total revenue 1427 1304 1213 1337 1216
Revenue 1427 1304 1213 1337 1216
Cost of Revenue, Total 694 662 590 652 600
Gross Profit 733 642 623 685 616
Total Operating Expense 1184 1244 964 1082 873
Selling/General/Admin. Expenses, Total 260 253 256 256 232
Research & Development 64 75 69 84 59
Depreciation / Amortization 43 49 43 44 29
Unusual Expense (Income) 119 193 7 24 -63
Other Operating Expenses, Total 4 12 -1 22 16
Operating Income 243 60 249 255 343
Interest Income (Expense), Net Non-Operating -41 -42 -34 -30 -24
Net Income Before Taxes 202 18 215 225 319
Net Income After Taxes 131 17 174 172 248
Minority Interest 0 -2 -1 1 0
Net Income Before Extra. Items 131 15 173 173 248
Net Income 131 15 173 173 248
Income Available to Common Excl. Extra. Items 131 15 173 173 248
Income Available to Common Incl. Extra. Items 131 15 173 173 248
Diluted Net Income 131 15 173 173 248
Diluted Weighted Average Shares 222 222 228 234 232
Diluted EPS Excluding Extraordinary Items 0.59009 0.06757 0.75877 0.73932 1.06897
Dividends per Share - Common Stock Primary Issue 0.25 0.35715 0.19 0.37405 0.18
Diluted Normalized EPS 1.14865 1.1982 0.83772 0.90171 0.75862
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 1999 2094 1922 1848 1668
Cash and Short Term Investments 292 450 347 465 276
Cash 159 155 85 94 112
Cash & Equivalents 1 22 35 39 36
Short Term Investments 132 273 227 332 128
Total Receivables, Net 841 876 734 749 748
Accounts Receivable - Trade, Net 777 781 662 637 654
Total Inventory 776 695 757 568 528
Prepaid Expenses 74 65 58 49 57
Other Current Assets, Total 16 8 26 17 59
Total Assets 4471 4372 4135 3930 3497
Property/Plant/Equipment, Total - Net 1081 1146 1068 962 870
Property/Plant/Equipment, Total - Gross 2008 1955 1841 1690 1549
Accumulated Depreciation, Total -927 -809 -773 -728 -679
Goodwill, Net 389 285 289 282 279
Intangibles, Net 735 607 587 552 487
Long Term Investments 52 46 34 29 38
Other Long Term Assets, Total 215 194 235 257 155
Total Current Liabilities 1077 1016 1028 1471 893
Accounts Payable 291 262 279 286 263
Accrued Expenses 171 194 175 173 185
Notes Payable/Short Term Debt 75 64 117 60 65
Current Port. of LT Debt/Capital Leases 73 57 51 518 10
Other Current Liabilities, Total 467 439 406 434 370
Total Liabilities 2336 1919 2000 1813 1812
Total Long Term Debt 1135 725 764 107 562
Long Term Debt 1074 651 692 48 539
Capital Lease Obligations 61 74 72 59 23
Deferred Income Tax 19 24 31 20 16
Minority Interest 13 14 13 12 12
Other Liabilities, Total 92 140 164 203 329
Total Equity 2135 2453 2135 2117 1685
Common Stock 40 42 41 41 40
Additional Paid-In Capital 282 282 282 282 282
Retained Earnings (Accumulated Deficit) 2129 2353 2011 2030 1618
Treasury Stock - Common 0 -1 -1
Other Equity, Total -316 -224 -199 -235 -254
Total Liabilities & Shareholders’ Equity 4471 4372 4135 3930 3497
Total Common Shares Outstanding 220.236 231.498 230.458 242.319 241.455
Jun 2023 Dec 2022 Jun 2022 Dec 2021 Jun 2021
Total Current Assets 2176 1999 2144 2094 1955
Cash and Short Term Investments 294 292 393 450 346
Cash & Equivalents 0 1 23 22 2
Short Term Investments 181 132 94 273 101
Total Receivables, Net 905 841 893 811 780
Accounts Receivable - Trade, Net 846 777 784 719 693
Total Inventory 859 776 765 695 736
Prepaid Expenses 85 74 80 65 78
Other Current Assets, Total 33 16 13 73 15
Total Assets 4619 4471 4747 4372 4180
Property/Plant/Equipment, Total - Net 1087 1081 1132 1146 1061
Goodwill, Net 390 389 394 285 286
Intangibles, Net 694 735 857 607 620
Long Term Investments 51 52 52 46 36
Other Long Term Assets, Total 221 215 168 194 222
Total Current Liabilities 1215 1077 1010 1016 960
Accounts Payable 291 255 262 226
Accrued Expenses 171 160 194 145
Notes Payable/Short Term Debt 113 75 76 64 132
Current Port. of LT Debt/Capital Leases 108 73 61 57 49
Other Current Liabilities, Total 489 467 458 439 408
Total Liabilities 2430 2336 2571 1919 1890
Total Long Term Debt 1091 1135 1414 725 751
Long Term Debt 1032 1074 1340 651 676
Capital Lease Obligations 59 61 74 74 75
Deferred Income Tax 26 19 24 24 21
Minority Interest 13 13 15 14 13
Other Liabilities, Total 85 92 108 140 145
Total Equity 2189 2135 2176 2453 2290
Common Stock 40 40 41 42 41
Additional Paid-In Capital 282 282 282 282 282
Retained Earnings (Accumulated Deficit) 2183 2129 2143 2353 2197
Treasury Stock - Common 0
Other Equity, Total -316 -316 -290 -224 -230
Total Liabilities & Shareholders’ Equity 4619 4471 4747 4372 4180
Total Common Shares Outstanding 220.988 220.236 220.113 231.498 231.432
Cash 113 159 276 155 243
Payable/Accrued 505
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line 233 544 558 491 293
Cash From Operating Activities 530 638 464 472 430
Cash From Operating Activities 372 145 91 73 69
Amortization 26 40
Non-Cash Items 112 108 84 34 116
Cash Taxes Paid 55 129 61 108 63
Cash Interest Paid 68 50 39 44 51
Changes in Working Capital -187 -159 -269 -152 -88
Cash From Investing Activities -607 -238 -283 -151 -96
Capital Expenditures -225 -229 -224 -186 -139
Other Investing Cash Flow Items, Total -382 -9 -59 35 43
Cash From Financing Activities -58 -287 -298 -155 -278
Financing Cash Flow Items -77 -53 -34 -48 -53
Total Cash Dividends Paid -125 -120 -109 -97 -84
Issuance (Retirement) of Stock, Net -303 0 -375
Issuance (Retirement) of Debt, Net 447 -114 220 -10 -141
Foreign Exchange Effects -21 -10 -2 0 -7
Net Change in Cash -156 103 -119 166 49
Dec 2022 Jun 2022 Dec 2021 Jun 2021 Dec 2020
Net income/Starting Line 233 215 544 319 558
Cash From Operating Activities 530 169 638 224 464
Cash From Operating Activities 372 95 145 44 91
Amortization
Non-Cash Items 110 48 108 28 84
Cash Taxes Paid 55 44 129 88 61
Cash Interest Paid 68 27 50 25 39
Changes in Working Capital -185 -189 -159 -167 -269
Cash From Investing Activities -607 -506 -238 -104 -283
Capital Expenditures -225 -119 -229 -94 -224
Other Investing Cash Flow Items, Total -382 -387 -9 -10 -59
Cash From Financing Activities -58 291 -287 -112 -298
Financing Cash Flow Items -77 -33 -53 -26 -34
Total Cash Dividends Paid -125 -83 -120 -78 -109
Issuance (Retirement) of Debt, Net 447 710 -114 -8 220
Foreign Exchange Effects -21 -9 -10 -9 -2
Net Change in Cash -156 -55 103 -1 -119
Issuance (Retirement) of Stock, Net -303 -303 0 0 -375

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Hikma Company profile

Discover the latest Hikma share price today with our comprehensive live chart.

Hikma Pharmaceuticals plc. (HIK) creates and sells generic pharmaceutical solutions and products in the USA, North Africa, Europe, and the Middle East; with its headquarters located in London, UK. The company has operations in more than 50 countries and divides its work into three business units: Branded, Injectables, and Generics.

Hikma owns 29 manufacturing plants in 11 countries: Jordan, Saudi Arabia, Algeria, Egypt, Morocco, Tunisia, Sudan, United States, Portugal, Italy and Germany. The Hikma’s branded division offers 499 products in 1,256 dosage strength. The most popular products are: Amoclan, Omnisef, Blopress and Suprax. The injectables division vendors 200 products in 379 dosage forms.

Hikma pharmaceuticals share price is set and traded on the London Stock Exchange (LSE) under the ticker symbol HIK. The company constitutes the FTSE 100 and FTSE 350 Indices.

Hikma made an initial public offering on 11 November 2005, and Hikma pharmaceuticals shares were listed for the first time, raising gross proceeds of $124 million.

Hikma Pharmaceuticals was founded in Amman, Jordan, by Samih Darwazah in 1978. In August 1996, it became the first Arab company to export pharmaceutical products to the US.

The company’s biggest acquisitions include Jazeera Pharmaceutical, Saudi Arabia; Instituto Biochimico Pavese Pharma, Italy; Baxter International, US; Ribosepharm, Germany; Promopharm, Morocco, and Alkan Pharma, Egypt. All of these strategic acquisitions helped Hikma to establish itself as the world’s leading provider in its industry.

In May 2014, Hikma Pharmaceuticals plc significantly increased its presence in the injected medicine market by purchasing assets from the US generic injectable drugs business of Germany's Boehringer Ingelheim for up to $300 million.

The most recent company acquisition was Roxane Laboratories in Columbus, US. It has majorly improved Hikma's position in a non-injectables business in the US market.

Hikma has been recognised as the Company of the Year by the Global Generics and Biosimilars Awards for four years in a row: from 2014 to 2017. 

According to Hikma’s latest earnings report, the company delivered strong growth in revenue and profit in 2019 with a group core revenue of $2,203 million (up 6 per cent) and operating profit of $508 million (up 10 per cent).

Follow the Hikma share price today with Capital.com to spot the best trading opportunities. Track all the ups and downs of the HIK stock price and stay on top of the latest price fluctuations with our live Hikma stock chart.

Industry: Pharmaceuticals (NEC)

1 New Burlington Place
LONDON
W1S 2HR
GB

Income Statement

  • Annual
  • Quarterly

News

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024

How escalating geopolitical tensions are impacting oil markets

The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

13:34, 4 April 2024

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

People also watch

Gold

2,382.55 Price
+1.630% 1D Chg, %
Long position overnight fee -0.0187%
Short position overnight fee 0.0105%
Overnight fee time 21:00 (UTC)
Spread 0.50

BTC/USD

63,122.40 Price
-1.170% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

US100

17,639.20 Price
-1.650% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 1.8

ETH/USD

3,078.39 Price
+0.170% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

Still looking for a broker you can trust?

Join the 610,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading